Penn Davis McFarland’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Penn Davis McFarland’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,565	Closed	-$262K	–	48
2023 Q2	$262K	Hold	2,565	–	–	0.05%	42
2023 Q1	$233K	Buy	+2,565	New	+$151K	0.04%	43
2021 Q4	–	Sell	-2,565	Closed	-$258K	–	46
2021 Q3	$258K	Hold	2,565	–	–	0.05%	43
2021 Q2	$363K	Hold	2,565	–	–	0.06%	39
2021 Q1	$256K	Sell	2,565 -1,283	-33%	-$150K	0.05%	42
2020 Q4	$476K	Hold	3,848	–	–	0.1%	34
2020 Q3	$375K	Hold	3,848	–	–	0.1%	35
2020 Q2	$600K	Hold	3,848	–	–	0.16%	32
2020 Q1	$555K	Sell	3,848 -1,283	-25%	-$248K	0.19%	28
2019 Q4	$1.05M	Buy	+5,131	New	+$936K	0.31%	23

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Penn Davis McFarland's RETA Position: Q3 2023 in Review

Penn Davis McFarland sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,565 shares — an estimated $262K sold.

Penn Davis McFarland first reported a position in RETA in Q4 2019 and held it in 10 quarters. The position peaked at $1.05M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Penn Davis McFarland reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Penn Davis McFarland sold 2,565 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $262K.
Penn Davis McFarland first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 10 quarters.
Penn Davis McFarland's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.05M in Q4 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Penn Davis McFarland's 13F filing for Q3 2023, filed 19 Oct 2023.